CriteriaEndocrinology and nutrition

Vascular protection in diabetes (Diabetes Canada 2018)

Shows which people with diabetes meet criteria for a statin, ACE inhibitor/ARB, aspirin and SGLT2i/GLP-1 RA to lower cardiovascular risk.

Updated 31 October 2026

When to use it

Review of cardioprotective therapy in adults with type 1 or type 2 diabetes.

Warning

Based on the 2018 chapter; later Diabetes Canada updates broaden SGLT2i and GLP-1 RA indications (heart failure, chronic kidney disease, high risk). Check the current version.

What it needs

  • Diabetes typeOptions: Type 1 · Type 2
  • AgeUnits: años
  • Clinical cardiovascular disease (coronary, cerebrovascular or peripheral arterial)Yes or no
  • Microvascular complications (retinopathy, nephropathy, neuropathy)Yes or no
  • Diabetes duration over 15 yearsYes or no
  • Another cardiovascular risk factor or end-organ damageYes or no
  • A1C above target on current therapyYes or no
  • Estimated GFR > 30 mL/min/1.73 m²Yes or no

The points for each answer and the automatic total are in the app.

How to interpret it

Statin
Interpretation
Not indicated by these criteria; assess overall risk
Indicated (LDL target < 2.0 mmol/L or > 50 % reduction)

In the app it also calculates: ACE inhibitor or ARB (vascular-protective dose), Aspirin 81–162 mg, SGLT2 inhibitor or GLP-1 RA with proven cardiovascular benefit.

Practical tip

Besides drugs, the guideline stresses overall control: healthy behaviours, blood pressure, glycaemia and smoking cessation.

3 more practical tips in the app.

Reference

A support tool for healthcare professionals: it guides and does not replace clinical judgement.

Back to top